Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $62.5 million, up 24% from $50.3 million in Q1 2024 [7][10] - Net product sales of Lupkinus were $60 million, a 25% increase from $48.1 million in the same period of 2024 [7][8] - Cash flow generated from operations was $1.3 million compared to a negative $18.6 million in Q1 2024; excluding restructuring payments, cash flow was $12.4 million [8][10] - The company had cash, cash equivalents, restricted cash, and investments of $312.9 million as of March 31, 2025, down from $358.5 million at the end of 2024 [9][10] - Net income was $23.3 million or $0.17 per share, compared to a net loss of $10.7 million or $0.07 per share in Q1 2024 [12] Business Line Data and Key Metrics Changes - The increase in net product sales of Lupkinus was primarily due to a rise in the number of cartons sold to specialty pharmacies and greater penetration in the lupus nephritis market [8][9] - Cost of revenue for Q1 2025 was $8.6 million, up from $7.8 million in Q1 2024, while gross margin improved to 86% from 85% [11][12] - Total operating expenses decreased to $40.6 million from $63.6 million in the same period of 2024, attributed to lower personnel expenses and reduced R&D costs [11][12] Market Data and Key Metrics Changes - The company is focused on educating rheumatologists about the benefits of initiating Lupkinus earlier in treatment, following updated guidelines from the American College of Rheumatology [9] - The company anticipates continued growth in the lupus nephritis market, supported by recent guideline updates that favor earlier diagnosis and treatment [26][52] Company Strategy and Development Direction - The company is maintaining a focus on commercial execution and operational efficiency, with a strong emphasis on the growth of Lupkinus [6][9] - The company reiterated its total revenue guidance for 2025 in the range of $250 million to $260 million and net product sales guidance of $240 million to $250 million [9][10] - The company is on track to report initial results from the Phase 1 study of AUR-200, a dual BAP inhibitor, later in the quarter [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Lupkinus, citing improvements in patient adds and rheumatology prescribing [17][18] - The company is closely monitoring potential impacts from government policies and tariffs, with minimal expected impact on costs due to existing stockpiles in the U.S. [31][32] - Management emphasized the importance of maintaining a competitive profile against new entrants in the lupus nephritis market [52][53] Other Important Information - The company has repurchased $5.8 million of its common shares in Q1 2025, part of a broader share repurchase program [9][10] - The company is actively defending its patents against ANDA filers and is committed to maintaining its revenue stream from Lupkinus [26][56] Q&A Session Summary Question: Can you discuss the quarterly cadence for Lupkinus sales and what is driving current sales? - Management indicated that sales are driven by a combination of new patient adds and persistency, with historical patterns suggesting a rise in sales in the latter half of the year [15][17] Question: What are the expectations for the second quarter compared to the first? - Management noted that Q1 is not typically the lowest quarter, with historical trends indicating a soft summer followed by a rise in Q4 [23][24] Question: Can you elaborate on the ANDA filers challenging the dosing protocol patent? - Management confirmed that they are vigorously defending their patents and that the process includes a 30-month stay for the filers [26] Question: What is the company's exposure to potential new federal government policies? - Management stated that they are monitoring the situation closely, with minimal expected impact on costs due to existing stockpiles in the U.S. [29][31] Question: What endpoints are anticipated to differentiate AUR-200 from other inhibitors? - Management indicated that the Phase 1 results will provide critical pharmacokinetic and pharmacodynamic data, which will help assess AUR-200's competitive profile [59]

Financial Data and Key Metrics Changes - For Q1 2025, total revenue was $62.5 million, up 24% from $50.3 million in Q1 2024 [5] - Net product sales of Lupkinus were $60 million, up 25% from $48.1 million in the same period of 2024 [5] - Cash flow generated from operations was $1.3 million compared to a negative $18.6 million in Q1 2024; excluding restructuring payments, cash flow was $12.4 million [5][6] - Net income was $23.3 million or $0.17 per share, compared to a net loss of $10.7 million or $0.07 per share in Q1 2024 [10] Business Line Data and Key Metrics Changes - The increase in net product sales of Lupkinus was primarily due to a rise in the number of cartons sold to specialty pharmacies and greater penetration in lupus nephritis treatment [5] - Cost of revenue for Q1 2025 was $8.6 million, up from $7.8 million in Q1 2024, while gross margin improved to 86% from 85% [9] Market Data and Key Metrics Changes - The company has seen improvements in rheumatology prescribing, indicating early diagnosis and treatment trends [16] - The American College of Rheumatology updated guidelines recommending the incorporation of drugs like Lupkinus into first-line therapy, which is expected to drive further growth [6] Company Strategy and Development Direction - The company is focused on commercial execution and operational efficiency, aiming for continued growth in Lupkinus sales and advancing the AUR 200 clinical program [6][11] - Total revenue guidance for 2025 is maintained in the range of $250 million to $260 million, with net product sales guidance of $240 million to $250 million [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for Lupkinus, citing historical performance patterns and ongoing improvements in patient treatment initiation [15][16] - The company is closely monitoring potential impacts from new federal government policies and tariffs, with minimal expected impact on operations due to existing stockpiles in the U.S. [29][30] Other Important Information - The company repurchased $5.8 million of its common shares in Q1 2025, part of a broader share repurchase program [6][9] - The company is on track to report initial results from the Phase 1 study of AUR 200 later in the quarter [7] Q&A Session Summary Question: Can you discuss the quarterly cadence for Lupkinus sales and what is driving sales? - Management indicated that sales are driven by a combination of new patient additions and persistency, with historical patterns suggesting a rise in sales in the latter half of the year [15] Question: What are the expectations for the second quarter compared to the first? - Management clarified that Q1 is not typically the lowest quarter, with historical trends indicating a soft summer followed by a rise in Q4 [21][22] Question: Can you elaborate on the ANDA filers challenging the dosing protocol patent? - The company is actively defending its patents and has filed infringement lawsuits against ANDA filers, with ongoing litigation expected [24] Question: What is the company's exposure to potential tariffs and government reimbursement policies? - The company has several years of product stockpiled in the U.S. and does not anticipate significant impact from tariffs on overall costs [29][30] Question: What endpoints are expected to differentiate AUR 200 from other inhibitors? - The Phase 1 results will provide insights into pharmacokinetics and pharmacodynamics, which will help assess AUR 200's competitive profile [60]

Company Performance - Aurinia Pharmaceuticals reported quarterly earnings of $0.16 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, compared to a loss of $0.03 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $62.47 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.63%, and showing an increase from year-ago revenues of $50.3 million [2] - Over the last four quarters, Aurinia has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - Aurinia shares have declined approximately 10.9% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $64.76 million, and for the current fiscal year, it is $0.44 on revenues of $258.28 million [7] Industry Context - The Medical - Drugs industry, to which Aurinia belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Performance - For the three months ended March 31, 2025, net product sales were $60.0 million, up 25% from $48.1 million in the same period of 2024[66]. - Total revenue for the three months ended March 31, 2025, was $62.5 million, an increase of 24% from $50.3 million in the same period of 2024[69]. - Gross margin for the three months ended March 31, 2025, was 86%, compared to 85% in the same period of 2024[78]. Cash Flow and Position - Cash flow provided by operating activities was $1.3 million for the three months ended March 31, 2025, compared to $(18.6) million in the same period of 2024[67]. - As of March 31, 2025, the cash position was $312.9 million, down from $358.5 million at December 31, 2024[68]. - Excluding restructuring payments, cash flow generated from operations was $12.4 million for the three months ended March 31, 2025[88]. - Future operations are expected to be funded by existing cash or cash generated from operations[89]. - Additional capital may be raised through equity or debt financings if necessary, but favorable terms are not guaranteed[90]. Expenses - Selling, general and administrative (SG&A) expenses decreased to $20.3 million for the three months ended March 31, 2025, from $47.7 million in the same period of 2024[80]. - Research and development (R&D) expenses increased to $5.7 million for the three months ended March 31, 2025, compared to $5.6 million in the same period of 2024[83]. - Restructuring expenses were $1.5 million for the three months ended March 31, 2025, down from $6.7 million in the same period of 2024[86]. - The company expects SG&A expenses to remain low in 2025 as it realizes the benefits of strategic restructuring efforts[81]. - The company anticipates an increase in R&D expenses as it advances the AUR200 program through clinical development[84]. Share Repurchase - The company repurchased 5.8 million common shares for $47.4 million during the three months ended March 31, 2025[88]. Accounting Policies - There have been no material changes to critical accounting policies or market risk disclosures since the Annual Report for the year ended December 31, 2024[91][94].

Core Insights - Aurinia Pharmaceuticals has experienced management changes, but activist investors believe these changes are insufficient despite the upward trend in Lupkynis sales [1] Company Overview - Aurinia Pharmaceuticals is focused on the sales performance of its product Lupkynis, which continues to show growth [1]

Financial Data and Key Metrics Changes - For Q4 2024, total revenue was $59.9 million, up 33% from $45.1 million in Q4 2023 [8][16] - For the full year 2024, total revenue was $235.1 million, up 34% from $175.5 million in 2023 [8][16] - Net product sales of LUPKYNIS for Q4 2024 were $57.6 million, up 36% from $42.3 million in Q4 2023 [9] - For the full year 2024, net product sales were $216.2 million, up 36% from $158.5 million in 2023 [9] - Cash flow from operations for Q4 2024 was $30.1 million, compared to $14.3 million in Q4 2023 [10] - Cash flow from operations for the full year 2024 was $44.4 million, compared to cash flow used in operations of $33.5 million in 2023 [10] - As of December 31, 2024, cash, cash equivalents, restricted cash, and investments totaled $358.5 million [11][17] - Gross margin for Q4 2024 was 91%, compared to 88% in Q4 2023; for the full year 2024, gross margin was 88%, down from 92% in 2023 [20] Business Line Data and Key Metrics Changes - The increase in net product sales of LUPKYNIS was primarily due to an increase in the number of cartons sold to specialty pharmacies [9] - Cost of revenue for Q4 2024 was $5.6 million, compared to $5.4 million in Q4 2023; for the full year 2024, cost of revenue was $28.2 million, up from $14.1 million in 2023 [19] Company Strategy and Development Direction - The company has a commercial strategy focused on four key growth drivers: expanding business at academic medical centers, targeting key rheumatology prescriber segments, leveraging new ACR lupus nephritis treatment guidelines, and improving continuity of care for lupus nephritis patients [12][13] - The company expects total revenue for 2025 to be in the range of $250 million to $260 million and net product sales in the range of $240 million to $250 million [14] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth of LUPKYNIS, citing a strong sales growth of 36% in 2024 and a solid position to start 2025 [12][14] - Management noted that historical financial results provide sufficient insight into the health of the business for projecting future results [11][58] Other Important Information - The company initiated a Phase 1 study for AUR200 in September 2024, with initial results expected in Q2 2025 [14][15] - The company has repurchased approximately 9.7 million common shares for about $70 million since the launch of the share repurchase program in Q1 2024 [18] Q&A Session Summary Question: Details on maximizing LUPKYNIS opportunity with current sales force - Management highlighted a focus on high prescribing rheumatology offices and the importance of the new ACR guidelines for early diagnosis and treatment [25][30] Question: Expectations for AUR200 data in Q2 - Management indicated that normal pharmacodynamics and pharmacokinetic data are expected, which will inform the next steps in the study [26][32] Question: Growth expectations for LUPKYNIS beyond 2025 - Management refrained from providing long-term guidance but emphasized historical trends as a basis for future projections [36][38] Question: Initial two months of 2025 and commercial outlook - Management stated that the guidance range is based on current market observations and historical financial results [46][49] Question: Decision to stop reporting PSS metrics - Management explained that after five years on the market, historical results provide sufficient insight for future projections [54][58] Question: Impact of ACR treatment guidelines on prescriber behavior - Management noted that over 50% of prescriptions come from rheumatologists, with expectations for gradual improvement in treatment behaviors [65][70] Question: Timeline for AUR200 studies - Management indicated that timelines will be clearer after the completion of the single-ascending dose study [66][72]

Financial Performance - For the year ended December 31, 2024, net product sales were $216.2 million, up 36% from $158.5 million in 2023[18]. - Total revenue was $235.1 million, a 34% increase from $175.5 million in 2023[1]. - License, collaboration, and royalty revenue was $18.9 million, an 11% increase from $17.0 million in 2023, driven by manufacturing services provided to Otsuka[1][4]. - Gross margin for 2024 was 88%, down from 92% in 2023[1][5]. - Net income for 2024 was $5.8 million, a significant improvement from a net loss of $78.0 million in 2023[1]. - Total operating expenses decreased to $239.8 million from $267.2 million in 2023, a reduction of $27.4 million[1]. - Research and development expenses decreased to $20.8 million from $49.6 million in 2023, primarily due to strategic restructuring efforts[1][6]. - Restructuring expenses for 2024 were $23.1 million, compared to nil in 2023, following a headcount reduction of approximately 25%[1][7]. - The company expects SG&A expenses to decrease in 2025 as it realizes the benefits of its strategic restructuring efforts[1][9]. Cash and Investments - As of December 31, 2024, Aurinia had cash, cash equivalents, restricted cash, and investments of $358.5 million, compared to $350.7 million at December 31, 2023[21]. - The company has cash, cash equivalents, restricted cash, and investments totaling $358.5 million as of December 31, 2024, with LUPKYNIS being the only approved product generating net sales[140]. - A hypothetical 1% increase or decrease in interest rates would have resulted in a $2.8 million fluctuation of annual interest income in the investment portfolio[206]. - The Company recognized a $72.5 million finance lease liability related to the Monoplant agreement, which is denominated in Swiss Francs[207]. - A hypothetical 10% increase or decrease in the Swiss Franc compared to the U.S. dollar would have a $7.5 million fluctuation in the valuation of the lease liability[207]. - The Company maintains cash balances with reputable financial institutions and has not experienced any losses associated with credit risk[209]. - The investment policy limits excess cash investments to certain types of instruments, ensuring a conservative approach to managing financial risk[209]. Product Development and Regulatory Approvals - Aurinia entered into a collaboration and licensing agreement with Otsuka for the development and commercialization of LUPKYNIS in multiple territories, receiving a $50 million upfront cash payment[22]. - Otsuka has obtained regulatory approval for LUPKYNIS in Japan, the EU, the UK, and Switzerland[24]. - AUR200 is being developed as a dual inhibitor of BAFF and APRIL for the potential treatment of autoimmune diseases[43]. - AUR200 has shown high binding affinity for both BAFF and APRIL compared to competitor inhibitors[47]. - The American College of Rheumatology now recommends triple immunosuppressive therapy, including calcineurin inhibitors like LUPKYNIS, as first-line therapy for lupus nephritis[42]. - LUPKYNIS demonstrated a significantly higher rate of complete renal response compared to standard treatments in the pivotal Phase 3 AURORA 1 study[35]. - AUR200 demonstrated an IC50 of 0.02 nM, significantly outperforming Atacicept (0.38 nM, 19.0x) and Telitacicept (1.05 nM, 52.5x) in preclinical testing[52]. - AUR200 resulted in significant and sustained reductions in B cell antibodies IgA and IgM in non-human primates, with no adverse findings reported[52]. - The New Chemical Entity (NCE) exclusivity for LUPKYNIS in the U.S. extends until January 22, 2026, providing 5 to 7.5 years of market exclusivity[56]. - NCE-equivalent exclusivity for voclosporin in certain European countries provides 10 years of exclusivity post-approval, with 8 years in Japan[57]. - The construction of a dedicated manufacturing facility for voclosporin (Monoplant) began in January 2021, with manufacturing commencing in June 2023[65]. - The company pays a quarterly fixed facility fee of approximately $4.0 million for the exclusive right to use the Monoplant through March 31, 2030[65]. Market and Competitive Landscape - LUPKYNIS is the only FDA-approved oral therapy for adult patients with active lupus nephritis, facing competition from injectable treatments and off-label therapies[62]. - The commercial success of LUPKYNIS is heavily dependent on third-party reimbursement policies and pricing regulations in the U.S. and other markets[99]. - The potential market size for LUPKYNIS is based on prescription and sales data, and if the market size is smaller than estimated, commercial prospects may be limited[91]. - LUPKYNIS's commercial prospects may be limited due to unfavorable pricing regulations and third-party reimbursement policies[101]. - The company reported various commercial metrics for LUPKYNIS, including the number of prescriptions and patient persistency rates, but these metrics do not directly correlate to financial performance[104]. - Net product sales are primarily from two specialty pharmacies and a distributor in the U.S., with revenue from collaboration partner Otsuka for the European and Japanese markets[105]. Legal and Regulatory Risks - A paragraph IV notice of certification was received on February 25, 2025, regarding a generic version of LUPKYNIS, alleging invalidity of the 2037 Patents[60]. - The company intends to vigorously defend LUPKYNIS and its intellectual property rights, which may delay FDA approval of any ANDA for 7.5 years from the NDA approval date[61]. - The company faces significant regulatory risks due to various foreign regulations governing clinical studies and commercial sales, which can differ substantially from U.S. FDA approval processes[75]. - The Inflation Reduction Act of 2022 includes drug pricing reforms that could significantly impact the company's future business, including a drug price negotiation program[79]. - The company may face product liability lawsuits, which could incur substantial liabilities and reduce LUPKYNIS sales[92]. - The company may face significant patent litigation costs due to a paragraph IV notice related to a generic version of LUPKYNIS, which could lead to a decline in net product sales[109]. - Compliance with ongoing post-marketing obligations for LUPKYNIS may lead to product recalls or increased regulatory actions, potentially affecting sales and costs[125]. - The company is subject to various federal, state, and foreign laws that could result in substantial penalties for noncompliance, impacting operations[133]. Operational and Strategic Initiatives - The company announced a strategic restructuring that reduced headcount by approximately 25% and later by an additional 45% to focus on LUPKYNIS growth and AUR200 development[117]. - The company relies on sole-source contract manufacturers for LUPKYNIS and AUR200, making uninterrupted supply critical for commercial success[127]. - The company faces risks related to reliance on third parties for distribution and clinical studies, which could delay commercialization efforts[128]. - The company has never paid dividends on common shares, and future dividends will depend on operational results and financial conditions[139]. - The company has not experienced material adverse effects from cybersecurity threats to date[156]. - Aurinia's business continuity program was refreshed in 2024 to enhance resilience against potential threats, including cyber-attacks[155]. - Aurinia's cybersecurity risk management program is part of its overall risk management framework, with regular assessments and updates to ensure security[152][155]. - The company’s Chief Information Officer has over 20 years of experience in information security and has been in the role since 2021[158]. - Management concluded that the disclosure controls and procedures were effective as of December 31, 2024[215]. Employee Relations - As of February 26, 2025, the company had 130 employees and maintains good relations with them, with no employees represented by labor unions[83].

Financial Data and Key Metrics Changes - For Q3 2024, total net revenue was $67.8 million, a 24% increase from $54.5 million in Q3 2023 [6][16] - Net product revenue for Q3 2024 was $55.5 million, up 36% from $40.8 million in Q3 2023 [6][17] - Cash flow from operations was approximately $17 million in Q3 2024, compared to a cash outflow of $13.3 million in Q3 2023 [7][16] - The company recorded a net income of $14.4 million, or $0.10 per share, compared to a net loss of $13.4 million, or $0.09 per share, in Q3 2023 [22] Business Line Data and Key Metrics Changes - The company added 364 PSFs and 146 new patients in Q3 2024, totaling 510, a 17% increase from 436 PSFs in Q3 2023 [8] - Total patients on LUPKYNIS therapy grew by 25%, reaching approximately 2,422 patients as of September 30, 2024, compared to 1,939 patients a year earlier [8] Market Data and Key Metrics Changes - The Japanese regulatory approval of LUPKYNIS triggered a $10 million milestone payment, with expectations of low double-digit royalties on net sales once launched in Japan [11] - Presentations at the American Society of Nephrology Kidney Week highlighted LUPKYNIS's role in treating lupus nephritis, particularly in affected populations [11][12] Company Strategy and Development Direction - The company is restructuring operations to enhance commercial and R&D efforts, aiming for a more focused operational strategy [13] - The restructuring will involve a workforce reduction of approximately 45%, with expected annualized cash-based operating expense savings of over $40 million [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business despite the restructuring, reaffirming 2024 revenue guidance [25] - The company anticipates continued growth driven by patient restarts and hospital-based sales, with a focus on maintaining high persistency rates [31] Other Important Information - The gross margin for Q3 2024 was 91%, compared to 88% in Q3 2023, while the gross margin for the first nine months of 2024 was 87%, down from 93% in the same period of 2023 [20] - Research and development expenses significantly decreased due to headcount reductions and the cessation of the AUR300 development program [21] Q&A Session Summary Question: Insights on restructuring and competitive positioning for AUR200 - Management clarified that the restructuring is based on a thorough review of business drivers and is not a sign of lack of confidence in the business [25][26] Question: Commentary on fourth quarter sales and guidance - Management feels comfortable with the current guidance range and noted potential factors affecting sales, including year-end insurance changes and holiday impacts [30] Question: Insights from the ENLIGHT-LN study on lupus nephritis treatment - Management indicated that the restart phenomenon is influenced by physician practices and guidelines, with expectations for increased persistency in treatment [31][32] Question: Dose levels and safety considerations for AUR200 - Management stated that dosing strategies will be determined through ongoing clinical studies, with a focus on balancing efficacy and safety [34] Question: Commentary on PSFs and sales environment - Management acknowledged the importance of PSFs but emphasized the need to consider restarts and hospital sales as part of the overall growth strategy [39]

Financial Performance - Total net revenue for Q3 2024 was $67.8 million, a 24.3% increase from $54.5 million in Q3 2023[119] - Product revenue for Q3 2024 was $55.5 million, up from $40.8 million in Q3 2023, representing a 36.1% increase[117] - Net income for Q3 2024 was $14.4 million, compared to a net loss of $13.4 million in Q3 2023, marking a significant turnaround[117] - Total net revenue for the nine months ended September 30, 2024, was $175.3 million, an increase of 34.4% from $130.4 million in the same period of 2023[119] - Net product revenue increased to $55.5 million for the three months ended September 30, 2024, compared to $40.8 million for the same period in 2023, and $158.6 million for the nine months ended September 30, 2024, compared to $116.2 million in 2023[121] Expenses and Cost Management - Operating expenses decreased to $56.0 million in Q3 2024 from $70.8 million in Q3 2023, a reduction of 20.9%[117] - SG&A expenses decreased to $42.4 million for the three months ended September 30, 2024, from $47.8 million in 2023, and to $135.0 million for the nine months ended September 30, 2024, from $145.0 million in 2023[128] - R&D expenses were $3.0 million for the three months ended September 30, 2024, down from $13.6 million in 2023, and $12.7 million for the nine months ended September 30, 2024, compared to $39.4 million in 2023[129] Strategic Restructuring - The company anticipates a one-time restructuring charge of approximately $15 to $19 million in Q4 2024, with expected annualized cash savings of over $40 million post-restructuring[107] - The workforce will be reduced by approximately 45% as part of the strategic restructuring to focus on LUPKYNIS growth and AUR200 development[107] Product Development and Market Performance - The average annualized net realizable revenue per patient for LUPKYNIS is estimated to be between $70,000 and $75,000[105] - The company recognized a $10 million milestone payment as collaboration revenue following the approval of LUPKYNIS in Japan[109] - The company is developing AUR200, a potential next-generation therapy for autoimmune diseases, with the first participant dosed in a Phase 1 study[108] - The number of patients on therapy increased to approximately 2,422 as of September 30, 2024, from approximately 1,939 as of September 30, 2023, with a 12-month persistency rate rising to 57% from 54%[122] Revenue Sources and Trends - The percentage of total net revenues from the two main specialty pharmacies was 81% for the three months ended September 30, 2024, up from 77% in 2023, and 87% for the nine months ended September 30, 2024, down from 90% in 2023[120] - License, collaboration, and royalty revenues were $12.3 million for the three months ended September 30, 2024, compared to $13.7 million in 2023, and $16.7 million for the nine months ended September 30, 2024, compared to $14.2 million in 2023[123] Financial Position and Cash Flow - Cash, cash equivalents, and restricted cash as of September 30, 2024, were approximately $37.1 million, down from $48.9 million at December 31, 2023, while investments increased to $311.6 million from $301.8 million[134] - Net cash provided by operating activities was $14.3 million for the nine months ended September 30, 2024, compared to net cash used of $47.8 million in 2023[137] - As of September 30, 2024, approximately 3.4 million common shares were repurchased for $18.6 million under the approved share repurchase program[141] Risk Factors - The company is exposed to foreign currency risk primarily with the Swiss franc, Canadian dollar, and Great Britain Pound, which could affect operating and financial results[149] - Inflation has been volatile and may continue to increase costs related to labor, manufacturing, and clinical trials, impacting overall financial performance[151] - The company does not believe that sudden changes in market interest rates would significantly affect its results of operations or cash flows due to the short-term nature of its investments[148] Other Financial Insights - The company had an $80.7 million finance lease liability related to the monoplant as of September 30, 2024, with a 10% fluctuation in the Swiss franc potentially causing an $8.1 million fluctuation in the lease liability valuation[150] - The company has not recognized any allowance for credit losses related to accounts receivable during the quarter ended September 30, 2024, indicating no issues with collectability[153] - The company's investment policy limits investments to highly rated financial institutions and aims for an overall rating of A-1 or higher by Standard & Poor's[152] - The timing between revenue recognition for product sales and receipt of payment is not significant, with standard credit terms ranging from 30 to 45 days[153] - There were no material impacts from foreign currency fluctuations on the company's financial condition or results of operations as of September 30, 2024[150] - The company monitors economic conditions and the creditworthiness of its main specialty pharmacies and collaboration partners[153]

Financial Performance - Total net revenue for Q3 2024 was $67.8 million, a 24% increase year-over-year, while net product revenue was $55.5 million, reflecting a 36% growth[1][6][7] - The company achieved $158.6 million in net product revenue for the nine months ended September 30, 2024, a 36% increase from $116.2 million in the same period of 2023[1][7] - Total revenue for the three months ended September 30, 2024, was $67,771,000, a 24% increase from $54,515,000 in the same period of 2023[28] - Product revenue for the nine months ended September 30, 2024, reached $158,604,000, compared to $116,218,000 for the same period in 2023, reflecting a 36% increase[28] - Net income for the three months ended September 30, 2024, was $14,350,000, compared to a net loss of $13,447,000 in the same period of 2023[28] - The company recorded a net income of $14.4 million or $0.10 per share for Q3 2024, compared to a net loss of $(13.4) million or $(0.09) per share in Q3 2023[1][15][16] - The company reported a basic net income per share of $0.10 for the three months ended September 30, 2024, compared to a loss of $0.09 per share in the same period of 2023[28] Cash Flow and Expenses - Cash flow from operations for Q3 2024 was $17.0 million, compared to a cash outflow of $(13.3) million in Q3 2023[1][18] - Operating expenses for the three months ended September 30, 2024, totaled $56,023,000, down from $70,778,000 in the same period of 2023, representing a 21% decrease[28] - SG&A expenses decreased to $42.4 million in Q3 2024 from $47.8 million in Q3 2023, primarily due to lower employee-related costs[1][12] - Research and development expenses for the three months ended September 30, 2024, were $3,047,000, significantly lower than $13,605,000 in the same period of 2023[28] - The company had a net cash provided by operating activities of $14,274,000 for the nine months ended September 30, 2024, compared to a net cash used of $47,773,000 in the same period of 2023[29] Market and Product Development - LUPKYNIS market penetration in the U.S. grew by 25% year-over-year, with 2,422 patients on therapy as of September 30, 2024[1][8] - AUR200, a new therapy for autoimmune diseases, began Phase 1 study in September 2024, with initial results expected in the first half of 2025[1][4] - License, collaboration, and royalty revenues included a $10 million milestone payment from Otsuka Pharmaceutical for LUPKYNIS approval in Japan[1][9] Assets and Liabilities - Cash, cash equivalents, and restricted cash decreased to $37,142,000 as of September 30, 2024, from $48,875,000 at the end of 2023[26] - Total current assets increased to $440,459,000 as of September 30, 2024, compared to $424,800,000 at the end of 2023, marking a 4% increase[26] - Total liabilities decreased to $161,359,000 as of September 30, 2024, from $170,108,000 at the end of 2023, indicating a 5% reduction[26] Future Outlook - The company anticipates a one-time restructuring charge of $15 to $19 million in Q4 2024, with expected annualized cash-based operating expense savings of over $40 million post-restructuring[1][22] - The gross margin for Q3 2024 was 91%, up from 88% in Q3 2023[1][11]